# Fulcrum Therapeutics share price today (Fulcrum Therapeutics, Inc., FULC)

> Fulcrum Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. FULC · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/fulc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.77 (−50.6% in a year)
- Revenue (Jun 2024): $80.0 M (+8,990.9% on a year ago)
- Profit (Jun 2024): $55.4 M
- Operating margin: 65.6% (+3,167.0 points on a year ago)
- ROE: −4%, FY24
- ROIC: −20.1%, against a 19.1% cost of capital: −39.2 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Fulcrum Therapeutics share price today? Fulcrum Therapeutics, Inc.'s share price was $3.77 at the close on 4 November 2026. That is 34.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $13, and at that close it sat 3% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 1 year the share price moved −52% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Fulcrum Therapeutics pay? Fulcrum Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Fulcrum Therapeutics on? Fulcrum Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Fulcrum Therapeutics profitable? Fulcrum Therapeutics, Inc. earned $55.4 M of net profit in the Jun 2024 quarter. The full FY24 year was a loss of $9.7 M. That is 69.3% of the quarter's revenue. The same quarter a year earlier lost $24.8 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Fulcrum Therapeutics make, and is it growing? Fulcrum Therapeutics, Inc. reported $80.0 M of revenue in the Jun 2024 quarter, +8,990.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 61.0% a year on average. The last full year, FY24, came in at $80.0 M. FY24 revenue was $80.0 M, +2,752.0% on the year before. Recent pace: the last four quarters grew +2,232.3% on average, against 61.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1,939.8%, against +120.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Fulcrum Therapeutics keep? Fulcrum Therapeutics, Inc.'s operating margin was 65.6% in the Jun 2024 quarter, 3,167.0 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +9,536.8 percentage points. Across 4 years it has been between −3,945.2% and −24.8%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +9,536.8 percentage points on the year while gross margin changed +5,644.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Fulcrum Therapeutics' profit turning into cash? Fulcrum Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used $2.2 M of cash, against −$9.7 M of profit. After $278 K of spending on assets, free cash was −$2.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Fulcrum Therapeutics' cash go? Fulcrum Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.7 M on assets over the last 3 years. Averaged over those years that is 1.1% of FY24 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.7 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Fulcrum Therapeutics' P/E ratio, and how does it compare with its own history? Fulcrum Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Fulcrum Therapeutics, Inc. at 3.6× its FY24 revenue of $80.0 M. The P/E comes back here once profit turns positive. ## Is the Fulcrum Therapeutics business getting better or worse? Fulcrum Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Fulcrum Therapeutics earn on its capital? Fulcrum Therapeutics, Inc. earned a ROE of −4% in FY24. That is up from a low of −55% in FY22. Its return on capital used (ROIC) is 39.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −12.2% net margin and 0.31× asset turnover (sales divided by assets). Why the return is what it is (FY24): a −12.2% net margin × 0.31× asset turnover × 1.07× leverage (assets divided by equity) ≈ −4.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −20.1% − 19.1% = −39.2 percentage points. The 19.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Fulcrum Therapeutics have too much debt? Fulcrum Therapeutics, Inc. has total debt of $5.3 M against shareholder equity of $311 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.07 in FY22 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Fulcrum Therapeutics shareholding pattern? 10.6% of Fulcrum Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Fulcrum Therapeutics from balance-sheet trouble? For Fulcrum Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Fulcrum Therapeutics rank in its industry? There is no score against its industry: Fulcrum Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Fulcrum Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Fulcrum Therapeutics in size? Fulcrum Therapeutics is the 176th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: vTv Therapeutics Inc., Ocugen, Inc. and SAB Biotherapeutics, Inc. Just below it: Inhibikase Therapeutics, Inc., Q32 Bio Inc. and Bicycle Therapeutics plc. ### Biotechnology companies close in size

1. [vTv Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/vtvt) $299 million
2. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million
3. [SAB Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/sabs) $289 million
4. Fulcrum Therapeutics, Inc. $288 million
5. [Inhibikase Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ikt) $285 million
6. [Q32 Bio Inc.](https://www.sectoralpha.in/us/stocks/qttb) $267 million
7. [Bicycle Therapeutics plc](https://www.sectoralpha.in/us/stocks/bcyc) $261 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Dave & Buster's Entertainment, Inc.](https://www.sectoralpha.in/us/stocks/play) $286 million · Entertainment
2. [CPI Card Group Inc.](https://www.sectoralpha.in/us/stocks/pmts) $286 million · Credit Services
3. Fulcrum Therapeutics, Inc. $285 million
4. [First Northern Community Bancorp](https://www.sectoralpha.in/us/stocks/fnrn) $285 million · Banks - Regional
5. [Gevo, Inc.](https://www.sectoralpha.in/us/stocks/gevo) $285 million · Specialty Chemicals

## What else do people ask about Fulcrum Therapeutics? ### What were Fulcrum Therapeutics's latest quarterly results? Fulcrum Therapeutics, Inc. reported revenue of $80.0 M and net profit of $55.4 M for the Jun 2024 quarter. Earnings per share were $0.87. The operating margin was 65.6%, 3,167.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Fulcrum Therapeutics's market cap? Fulcrum Therapeutics, Inc.'s market capitalisation is $288 M at a stock price of $3.77. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Fulcrum Therapeutics performing? Fulcrum Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Fulcrum Therapeutics's stock price go up? This page does not forecast Fulcrum Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $3.77. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Fulcrum Therapeutics in its business cycle? Fulcrum Therapeutics, Inc.'s FY24 operating margin was −24.8%, against a 4-year range of −3,945.2% to −24.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 65.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Fulcrum Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Fulcrum Therapeutics a stock worth studying right now? What the numbers show: Fulcrum Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.